Background High rates of virus transmission and the presence of variants of concern can affect vaccine effectiveness (VE). Both conditions occur in low-income countries, which primarily use viral vector or inactivated virus vaccine technologies. Such countries conducted few VE analyses, and most lack the power to evaluate effectiveness in subgroups.

3rd September 2021 • comment

Comments and recommendations for regulating the Nagoya Protocol in Brazil

by Braulio Dias, Manuela Souza and Luiz Marinello

Abstract Brazil deposited at the UN Secretariat its ratification of Nagoya Protocol on March 4, 2021. 90 (ninety) days from this date, the country becomes a member of the Nagoya Protocol, assuming rights and duties. This paper aims to contribute to the challenge that the country will have in harmonizing the Nagoya Protocol and its internal legal framework (Law 13.123/2015 regulated by Decree 8.772 /2016)

17th June 2021 • comment